Hisamitsu Pharmaceutical Co (4530.T) Stock Price
Hisamitsu Pharmaceutical Co Price
Over the last 19 years Hisamitsu Pharmaceutical Co grew revenue by 2.2% annually, reaching 156.01 B JPY. Earnings per share have grown at 3.3% per year over the last 19 years. For Hisamitsu Pharmaceutical Co, the net margin of 13.9% is up versus 8.1% a few years ago. At today's price the dividend yield works out to roughly 1.74%. The payout ratio is around 35% of earnings. The dividend has grown at 3.6% per year over the past 19 years. The consensus 12-month price target for Hisamitsu Pharmaceutical Co is 4,335.00 JPY, about 26.6% below where the stock trades today. Of 8 analysts, 0 rate the stock a buy — an overall Sell consensus.
Hisamitsu Pharmaceutical Co stock price
Hisamitsu Pharmaceutical Co business model & stock analysis
Frequently asked questions about Hisamitsu Pharmaceutical Co
The business model of Hisamitsu Pharmaceutical Co Inc focuses on the development, manufacturing, and sales of pharmaceutical products. As a leading Japanese pharmaceutical company, Hisamitsu Pharmaceutical specializes in producing transdermal therapeutic patches, such as the popular brand Salonpas. By utilizing innovative drug delivery systems and advanced research, the company aims to provide effective and convenient solutions for pain relief and healthcare. With a strong emphasis on quality and customer satisfaction, Hisamitsu Pharmaceutical continues to expand its product portfolio and global presence, addressing the diverse healthcare needs of individuals worldwide.
Hisamitsu Pharmaceutical Co Inc is primarily active in the pharmaceutical industry.
The main competitors of Hisamitsu Pharmaceutical Co Inc in the market include large pharmaceutical companies such as Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, and Astellas Pharma Inc. Additionally, other competitors may include global pharmaceutical companies like Pfizer Inc. and Novartis AG. These companies compete with Hisamitsu Pharmaceutical Co Inc in various therapeutic areas, including pain management and patches.
Hisamitsu Pharmaceutical Co Inc is a renowned Japanese company with a rich history and background in the pharmaceutical industry. Founded in 1847, Hisamitsu has been dedicated to providing innovative healthcare solutions to improve people's lives. With a focus on the development and manufacturing of pharmaceutical products, the company has established itself as a leader in transdermal drug delivery systems. Hisamitsu Pharmaceutical Co Inc has grown into a global entity, operating in various countries and expanding its product portfolio to include a wide range of over-the-counter medicines, medical devices, and prescription drugs. With a commitment to research, quality, and customer satisfaction, Hisamitsu continues to contribute to the advancement of healthcare worldwide.
Some significant milestones achieved by Hisamitsu Pharmaceutical Co Inc include the development of the world's first topical patch for pain relief, the launch of their flagship product Salonpas, which has become a globally recognized brand, and their continuous research and development efforts in pharmaceutical technology. Additionally, Hisamitsu Pharmaceutical Co Inc has expanded its global presence through strategic partnerships and acquisitions, strengthening its position in the international market. Their commitment to innovation and high-quality healthcare products has garnered them numerous accolades and recognition within the industry.
Hisamitsu Pharmaceutical Co Inc is primarily present in Japan, where it is headquartered and has a strong market presence. As a leading pharmaceutical company, Hisamitsu has expanded its operations internationally and is also present in various countries and regions worldwide. Some of the key markets where Hisamitsu Pharmaceutical Co Inc operates include the United States, Europe, China, Asia-Pacific, and other regions. With its diverse range of healthcare products and global reach, Hisamitsu Pharmaceutical Co Inc continues to contribute to the well-being of people across different countries and regions.
Hisamitsu Pharmaceutical Co Inc represents values of innovation, quality, and commitment to improving healthcare. With a strong corporate philosophy, the company aims to provide effective and safe pharmaceutical products to enhance people's well-being. Its focus on research and development has led to breakthroughs in drug delivery systems, including its flagship product, the PAIN PATCH. By continuously investing in technological advancements and maintaining high standards, Hisamitsu Pharmaceutical Co Inc sets itself apart as a trusted and reputable company in the pharmaceutical industry.
Analysts currently set an average price target of 4,335.00 JPY for the Hisamitsu Pharmaceutical Co stock (median: 4,335.00 JPY), implying -26.6 % versus the latest price. The consensus is based on 8 analyst ratings.
8 analysts currently rate the Hisamitsu Pharmaceutical Co stock: 0 recommend buying, 4 holding and 4 selling. For 2026, analysts expect Hisamitsu Pharmaceutical Co to generate revenue of 162.00 B JPY and earnings per share of 299.50 JPY.
Converted at the current exchange rate, the Hisamitsu Pharmaceutical Co share trades at 33.13 EUR (5,903.37 JPY).
The Hisamitsu Pharmaceutical Co share (4530.T) is listed on 3 stock exchanges, including: Tokio (JPX) (4530.T), Frankfurt (HPX.F).
Hisamitsu Pharmaceutical Co Inc is a Japanese company specializing in the manufacture and sale of pharmaceutical products. It has a wide range of medicines for the treatment of musculoskeletal, respiratory, cardiovascular, and skin disorders. The business model of Hisamitsu is based on researching and developing new drugs, as well as marketing and distributing these products globally. The company conducts research and development worldwide to continuously expand its product range and meet the needs of consumers. Hisamitsu's medicines are divided into different categories, including pain relief, dermatology, gastroenterology, and respiratory diseases. In the pain relief category, the company offers various products such as pain patches, ointments, and creams used to relieve joint pain, muscle soreness, and other pain symptoms. In the dermatology category, Hisamitsu produces innovative medications for the treatment of skin diseases such as acne, eczema, and dermatitis. In the gastroenterology category, Hisamitsu offers medications for the treatment of gastrointestinal disorders such as heartburn, acid reflux, and digestive disorders. In the respiratory diseases category, the company provides products for the treatment of conditions like asthma, chronic obstructive pulmonary disease (COPD), and seasonal allergic rhinitis. Hisamitsu has a wide distribution network and sells its products in over 60 countries worldwide. It collaborates with various partners, retailers, and health organizations to ensure that its products are available in every region globally. The company also operates an extensive research and development department to further develop its innovative medications. It invests significant resources in the search for new active ingredients that can be used to treat conditions that have not been addressed previously. Hisamitsu's business model also includes collaboration with other companies to develop and jointly market innovative products. Collaborating with other manufacturers allows Hisamitsu to diversify its product range and reach a broader customer base. Overall, Hisamitsu's business model is based on a combination of research and development, distribution partnerships, and a strong presence in the global market. With a wide range of innovative pharmaceutical products and a strong commitment to research and development of new medications, Hisamitsu Pharmaceutical Co Inc has established a leading position in the pharmaceutical industry and will play an important role in improving the health and well-being of people worldwide in the future.
The expected revenue of Hisamitsu Pharmaceutical Co is 162.00 B JPY. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Hisamitsu Pharmaceutical Co is 22.08 B JPY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Hisamitsu Pharmaceutical Co is currently 19.71. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Hisamitsu Pharmaceutical Co stock.
The price-to-sales ratio (P/S) of Hisamitsu Pharmaceutical Co is currently 2.69. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Hisamitsu Pharmaceutical Co stock.
The Eulerpool Quality Score for Hisamitsu Pharmaceutical Co is 4/10.
The ISIN of Hisamitsu Pharmaceutical Co is JP3784600003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Hisamitsu Pharmaceutical Co is 864341. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Hisamitsu Pharmaceutical Co is 4530.T. The ticker symbol is used to trade Hisamitsu Pharmaceutical Co shares on the stock exchange.
Hisamitsu Pharmaceutical Co stock
Hisamitsu Pharmaceutical Co Peer Group
Hisamitsu Pharmaceutical Co Ticker
Hisamitsu Pharmaceutical Co FIGI
All fundamentals and in-depth analysis of Hisamitsu Pharmaceutical Co
Our stock analysis for Hisamitsu Pharmaceutical Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hisamitsu Pharmaceutical Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.